RLMD

Relmada Therapeutics, Inc. Common Stock

3.55

USD

RLMD Earnings Reports

Positive Surprise Ratio

RLMD beat 10 of 22 last estimates.

45%

Next Report

Date of Next Report

Mar 25, 2026

Estimate for Q4 25 (Revenue/ EPS)

-$0.14

Implied change from Q3 25 (Revenue/ EPS)

-53.33%

Implied change from Q4 24 (Revenue/ EPS)

-77.42%

Relmada Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 13, 2025, RLMD reported earnings of -0.30 USD per share (EPS) for Q3 25, missing the estimate of -0.11 USD, resulting in a -153.59% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +1.80% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 4 analysts forecast an EPS of -0.14 USD, with revenue projected to reach -- USD, implying an decrease of -53.33% EPS, and increase of 0.00% in Revenue from the last quarter.

FAQ

What were Relmada Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Relmada Therapeutics, Inc. Common Stock reported EPS of -$0.30, missing estimates by -153.59%, and revenue of $0.00, 0% as expectations.

How did the market react to Relmada Therapeutics, Inc. Common Stock's Q3 2025 earnings?

The stock price moved up 1.8%, changed from $3.88 before the earnings release to $3.95 the day after.

When is Relmada Therapeutics, Inc. Common Stock expected to report next?

The next earning report is scheduled for Mar 25, 2026.

What are the forecasts for Relmada Therapeutics, Inc. Common Stock's next earnings report?

Based on 4 analysts, Relmada Therapeutics, Inc. Common Stock is expected to report EPS of -$0.14 and revenue of -- for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.